Source disclosure: February 26, 2026, 16:10 JST
Delta-Fly Pharma,Inc. [4598.T]
TOKYO, Feb 26 (Pulse News Wire) -- Delta-Fly Pharma, Inc. (4598.T), represented by President Sei Eshima, has announced significant exercise activity related to its Eleventh Tranche Warrant (with Exercise Price Adjustment Clause) issued on February 2, 2026, to Macquarie Bank Limited. The warrant exercises occurred between February 3 and February 26, 2026.
According to the company's announcement, during this period, 815,100 shares were delivered as a result of exercising 8,151 warrants out of the total 29,000 warrants issued. This represents an exercise ratio of 27.17% of the total number of warrants issued. As of February 3, 2026, there were 30,000 unexercised warrants, which now stands at 21,849 unexercised warrants after these recent activities.
The detailed exercise status since February 3 is provided below: - On February 3, 246 warrants were exercised without any share delivery. - On February 4, one warrant was exercised alongside the delivery of 100 shares. - From February 5 through February 17, no further exercises took place. - On February 18, 750 warrants were exercised with the delivery of 75,000 shares. - On February 26, a substantial exercise event saw 7,400 warrants being exercised with the issuance of 740,000 shares.
At the end of January 2026, before the commencement of these exercises, the outstanding shares stood at 12,159,900, including 198 treasury shares. These figures highlight the considerable impact of the warrant exercises on the company’s capital structure over the past month. For more information, interested parties can contact Director Kenichi Kurotaki of the Management Department via https://www.delta-flypharma.co.jp/ir/ircontact/.
AI-translated content. 🟢 Confidence: High See terms • Original filing